Share:

“Anyone can dream about the future. Interstellar space ships, laser swords, and alien races are a staple of science fiction, but it takes a lot of diligent research to craft a future that could actually come to pass. When Eidos-Montreal rebooted the Deus Ex series in 2011, it wanted to build a world that didn’t just feel real, but was a world that might become real in 15 to 20 years. The team knew they wouldn’t be able to do that on their own. In order to craft a believable near future, Deus Ex’s developers consulted with Will Rosellini, one of the leading biomechanical researchers in the field. However, Rosellini doesn’t fit the mold of a traditional scientist. This ex-pitcher for the Arizona Diamondbacks has spent over a decade and several million dollars engineering a future where machines can flawlessly make up for biological failings, and now he’s helping deliver that future with the Deus Ex series.”

Project designed to teach biomedical researchers at UT System institutions how to start new companies

CIRTEC Medical Systems, a leading provider of outsourced medical device manufacturing services for complex Class III implantable devices and minimally invasive devices, today announced plans to support a new UT Dallas-led initiative aimed at identifying potentially marketable biomedical technologies developed at University of Texas System institutions and moving them more efficiently from the laboratory bench to the bedside.

Share:

Company views Wallonia as ideal environment to expand R&D and manufacturing

nUro, Inc. (the “Company”) announced today that it has exercised its option to invest in Rosellini Scientific Benelux, SPRL. This marks the third investment in Wallonia by the company (two equity injections and one acquisition). nUro, Inc. plans to manufacture its line of neurostimulation devices in its rapid prototyping labs in Wallonia and in conjunction with its manufacturing partner Medi-Line.

Share:

UT Dallas, MD Anderson Cancer Center Team Up to Help Companies Commercialize Their Discoveries

A new UT Dallas-led initiative is aimed at identifying potentially marketable biomedical technologies developed at University of Texas System institutions and moving them more efficiently from the laboratory bench to the bedside.